Search Results - "Bajel, Ashish R."

CD19 Negative Relapse in B-ALL Treated with Blinatumomab Therapy: Avoiding the Trap by Yannakou, Costas K, Came, Neil, Bajel, Ashish R, Juneja, Surender

“…Acute lymphoblastic leukaemia of the B lineage (B-ALL) is an aggressive neoplasm of B lymphocyte precursors that expresses the pan B cell marker CD19 in the…”
Get full text

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome by Zeidan, Amer M., Pollyea, Daniel A, Garcia, Jacqueline S, Brunner, Andrew, Roncolato, Fernando, Borate, Uma, Odenike, Olatoyosi, Bajel, Ashish R., Watson, Anne Marie, Götze, Katharina, Nolte, Florian, Tan, Peter T., Hong, Wan-Jen, Dunbar, Martin, Zhou, Ying, Gressick, Lori, Ainsworth, William, Harb, Jason, Salem, Ahmed Hamed, Hayslip, John, Swords, Ronan, Garcia-Manero, Guillermo

“…▪ Introduction Over-expression of the anti-apoptotic protein BCL-2 in MDS has been implicated in progression and drug resistance in MDS. Venetoclax (Ven), a…”
Get full text

A Multicentre Study Investigating the Pharmacokinetics and Pharmacodynamics of Busulphan When Combined with Melphalan As Conditioning in Adult Autologous Transplant Recipients by Willcox, Abbey, Wong, Eric, Bajel, Ashish R, Harrison, Simon J., Hoyt, Rosemary Thurston, Janson, Brett, Nath, Christa, Shaw, Peter J, Ritchie, David, Grigg, Andrew

“…Busulfan (Bu) is an alkylating agent commonly used in conditioning regimens prior to allogeneic stem cell transplantation (SCT). Whilst systemic drug exposure…”
Get full text

Single-Centre Validation Of a Disease Risk Index For Estimating Survival and Relapse In Allogeneic Hematopoietic Stem Cell Transplant Recipients: Sample Size, Adequate Follow-Up, and Use Of Local Data Are Vital Considerations by Lim, Andrew B M, Roberts, Andrew W., Mason, Kate, Bajel, Ashish R., Szer, Jeffrey, Ritchie, David

“…Allogeneic hematopoietic stem cell transplantation (alloHSCT) is applied for a wide range of malignant hematologic diseases at a wide range of stages of…”
Get full text

Allogeneic Stem Cell Transplantation (allo-SCT) for Chronic Myelomonocytic Leukemia – a Multicentre Australian Experience: Prognostic Factors for Survival and Relapse by Bajel, Ashish R., Curley, Cameron, Lim, Andrew Boon Ming, Handunnetti, Sasanka, Getta, Bartlomiej, Thompson, Philip A, Wright, Matthew P.F., Greenwood, Matthew, Hertzberg, Mark S, Curtis, David J., Szer, Jeffrey, Kennedy, Glen A, Ritchie, David

“…Background: Chronic myelomonocytic leukemia (CMML) is an uncommon and heterogeneous disease with a varying clinical course. Treatment with hypomethylating…”
Get full text

Screening With Spirometry Is A Useful Predictor Of Later Development Of Non-Infectious Pulmonary Syndromes In Patients Undergoing Allogeneic Stem Cell Transplantation by Philip, Thompson A, Lim, Andrew B M, Tacey, Mark, Hijazi, Ramzi, Ng, Ashley P., Szer, Jeffrey, Ritchie, David, Bajel, Ashish R.

“…Non-infectious pulmonary syndromes (NIPS) frequently complicate allogeneic stem cell transplantation (alloSCT). The most common and serious is the…”
Get full text